| Literature DB >> 34149594 |
Sanathorn Chowsilpa1,2, Doris-Eva Bamiou1,3,4, Nehzat Koohi1,3,5.
Abstract
Background: Auditory temporal processing tests are key clinical measures in order to diagnose central auditory processing disorder (CAPD). Although these tests have been used for decades, there is no up-to-date evidence to determine the effectiveness of detecting the abnormalities in central auditory processing in adults while the available national CAPD guidelines predominantly address CAPD in the pediatric population. Purpose: To determine the efficacy of the auditory temporal ordering tests [duration pattern test (DPT) and frequency pattern test (FPT)], and a temporal resolution test [gaps-in-noise (GIN) test] for detecting the central auditory processing abnormalities in adults with documented brain pathology. Research Design: Systematic reviews and meta-analyses. Study samples: Four databases, including PubMed, Web of Science, Embase, and Scopus, were systematically searched. The publications in the English language that recruited adults (above 16 years old) with pathologic brain conditions and described the diagnostic tests for auditory temporal processing were selected for review. Data Collections and Analysis: All data were systematically evaluated, extracted, categorized, and summarized in tables. The meta-analysis was done in order to determine the effectiveness of the DPT, FPT, and GIN tests.Entities:
Keywords: auditory temporal processing; duration pattern test; frequency pattern test; gaps-in-noise test; temporal ordering test; temporal resolution test
Year: 2021 PMID: 34149594 PMCID: PMC8206525 DOI: 10.3389/fneur.2021.656117
Source DB: PubMed Journal: Front Neurol ISSN: 1664-2295 Impact factor: 4.003
Figure 1Preferred reporting items for systematic reviews and meta-analyses (PRISMA) flow diagram.
Figure 2Risk of bias and applicability concern summary following the QUADAS-2 (quality assessment of diagnostic accuracy studies) criteria.
Risk of bias evaluation results using the NOS for case control studies.
| Aravindkumar et al. ( | ⋆ | ⋆ | ⋆ | ⋆ | ⋆- | ⋆ | – | 6 |
| Bamiou et al. ( | ⋆ | ⋆ | ⋆ | ⋆ | ⋆⋆ | ⋆ | – | 7 |
| Elbeltagy et al. ( | – | ⋆ | ⋆ | ⋆ | ⋆⋆ | ⋆ | – | 6 |
| Jafari et al. ( | ⋆ | ⋆ | ⋆ | ⋆ | ⋆⋆ | ⋆ | – | 7 |
| Koohi et al. ( | ⋆ | ⋆ | ⋆ | ⋆ | ⋆⋆ | ⋆ | – | 7 |
| Lavasani et al. ( | ⋆ | ⋆ | ⋆ | ⋆ | ⋆⋆ | ⋆ | – | 7 |
| Meneguello et al. ( | – | ⋆ | ⋆ | ⋆ | ⋆⋆ | ⋆ | – | 6 |
| Musiek et al. ( | ⋆ | ⋆ | ⋆ | ⋆ | ⋆- | ⋆ | – | 6 |
| Musiek et al. ( | ⋆ | ⋆ | ⋆ | ⋆ | ⋆⋆ | ⋆ | – | 7 |
| Parson et al. ( | ⋆ | ⋆ | ⋆ | ⋆ | ⋆- | ⋆ | – | 6 |
| Rabelo et al. ( | ⋆ | ⋆ | ⋆ | ⋆ | ⋆- | ⋆ | – | 6 |
| Troche et al. ( | ⋆ | ⋆ | ⋆ | ⋆ | ⋆- | ⋆ | – | 6 |
| Turgeon et al., ( | ⋆ | ⋆ | ⋆ | ⋆ | ⋆- | ⋆ | – | 6 |
| Valadbeigi et al. ( | ⋆ | ⋆ | ⋆ | ⋆ | ⋆⋆ | ⋆ | – | 7 |
NOS, Newcastle–Ottawa Scale.
.
Tests for auditory temporal ordering or sequencing: DPT in participants with documented organic brain diseases.
| Yes | Participants in the disease group had insular stroke, confirmed by MRI. | — | Yes | |||
| RE = 89 ± 11 | RE = 43 ± 12 | — | ||||
| No | Normal-hearing participants with documented TLE, diagnosed by clinical history and several investigations. They were also treated with AEDs. | — | — | No | ||
| — | RTLE = 53.3% | — | ||||
| Yes | Participants in the disease group had history of stroke, confirmed by MRI. | Yes | ||||
| RE= 90.71 ± 7.16 | RE = 79.80 ± 9.35 | RE = 62.49 ± 9.54 | ||||
| RE = 72.1 ± 9.33 | ||||||
| Yes | Participants in disease groups were diagnosed TLE with normal hearing threshold. | Yes | ||||
| RE = 94.99 ± 4.9 | RE = 93.6 ± 6.04 | RE = 63.08 ± 2.2 | ||||
| RE = 76.51 ± 4.22 | ||||||
| Yes | All participants had normal hearing. Participants in the disease group were confirmed their diagnosis with TLE and prescribed AED. | — | Yes | |||
| RE = 85.2 ± 17.33 | RE = 53.25 ± 26.87 | — | ||||
| Yes | Participants in disease groups had mild to moderate Parkinson's disease [defined by Hoehn and Yahr ( | — | Yes | |||
| DurS = 92.50 ± 10.35 | DurS = 86.46 ± 24.69 | — | ||||
| Yes | Participants in disease groups had history of sport-related concussions, identified by the criteria from the American Academy of Neurology (Practice parameter 2000) and all athletes completed a Post-Concussive Symptom Checklist (Aubry et al., ( | — | No | |||
| N/A | Percent errors from 2 concussed subjects were 2 SD above those of the non-concussed group (subject 6: RE = 43% and LE = 17%; subject 8: RE = 13%) | — | ||||
| Yes | Participants in disease groups were diagnosed relapsing-remitting MS, by neurologists and MRI, with normal hearing threshold. | — | Yes | |||
| RE = 85.6 ± 6.5 | RE = 64.3 ± 6.9 | — | ||||
DPT, duration pattern test; M:F, male:female; AEDs, antiepileptic drugs; MS, multiple sclerosis; TLE, temporal lobe epilepsy; RE, right ear; LE, left ear; DurS, duration with small perceptual distance; DurL, duration with large perceptual distance; RTLE, right temporal lobe epilepsy; LTLE, left temporal lobe epilepsy. Age was presented in years: mean ± SD or mean (range).
Tests for auditory temporal resolution or discrimination: GIN test in participants with documented organic brain disease.
| Yes | All participants had normal hearing. Participants in disease group were diagnosed with refractory complex partial seizures and MTS. | Yes | ||||
| RE = 5.22 ± 1.11 | RE = 8.15 ± 2.34 | RE = 9.54 ± 3.67 | ||||
| RE = 8.85 ± 3.02 | ||||||
| Yes | Participants in disease group had insular stroke, confirmed by MRI | Yes | ||||
| RE = 4 ± 1 | RE = 8 ± 2 | RE = 11 ± 3 | ||||
| RE = 9.125 ± 2.20 | ||||||
| Yes | Participants in the disease group were diagnosed MS | — | Yes | |||
| RE = 4.4 ± 0.5 | RE = 9.1 ± 1.0 | — | ||||
| Yes | Participants in the disease group had history of stroke, confirmed by MRI. | Yes | ||||
| RE = 6.40 ± 1.84 | RE = 8.32 ± 3.21 | RE = 9.50 ± 2.39 | ||||
| RE = 8.84 ± 2.84 | ||||||
| Yes | Participants in disease groups had a history of stroke, confirmed by MRI. Their auditory functions were assessed at 3–12 months after the onset of stroke. | Yes | ||||
| RE = 5.94 ± 0.98 | RE = 7.93 ± 1.91 | |||||
| Yes | Participants in disease groups were diagnosed with TLE with normal hearing threshold. | Yes | ||||
| RE = 4.77 ± 0.54 | RE = 7.09 ± 2.2 | RE = 6.64 ± 2.9 | ||||
| RE = 6.84 ± 2.56 | ||||||
| Yes | All participants had normal hearing. Participants in the disease group had confirmed neurological involvement to central auditory processing. | — | No | |||
| RE = 4.9 (4–8) | RE = 8.5 (5–20) | — | ||||
| Yes | All participants had normal hearing. Participants in disease group were diagnosed mesial temporal sclerosis. | — | Yes | |||
| RE = 4.7 ± 1.0 | RE =7.4 ± 2.9 | — | ||||
| Yes | Participants in disease groups had a history of sport-related concussions, identified by using the criteria from the American Academy of Neurology (Practice parameter 2000) and all athletes completed a Post-Concussive Symptom Checklist (Aubry et al., ( | — | No | |||
| — | Percent of errors from 2 concussed subjects were 2 SD above those of the non-concussed group (subject 6: RE = 43% and LE=17%; subject 8: RE = 13%). | — | ||||
| Yes | Participants in disease groups were diagnosed relapsing-remitting MS, by neurologists and MRI, with normal hearing threshold. | — | No | |||
GIN, gaps-in-noise; M:F, male:female; MS, multiple sclerosis; MTS, mesial temporal sclerosis; TLE, temporal lobe epilepsy; RE, right ear; LE, left ear; DurS, duration with small perceptual distance; DurL, duration with large perceptual distance; RTLE, right temporal lobe epilepsy; LTLE, left temporal lobe epilepsy. Age was presented in years; mean ± SD.
Figure 3Forest plot of meta-analysis for duration pattern test (DPT), comparing between participants with documented brain disease and normal controls.
Figure 4Forest plot of duration pattern test (DPT) for sensitivity analysis after excluding the studies from Troche et al. (31).
Tests for auditory temporal processing: FPT in participants with documented organic brain diseases.
| Yes | Participants in the disease group had insular stroke confirmed by MRI. | Yes | |||
| RE = 97 ± 6 | RE = 41 ± 30 | ||||
| Yes | Participants in the disease group were diagnosed MS | Yes | |||
| RE = 85.8 ± 4.5 | RE = 70.3 ± 3.5 | ||||
| No | Normal-hearing participants with documented TLE, diagnosed by clinical history and several investigations. They were also treated with AEDs. | No | |||
| – | RTLE = 80% | ||||
| Yes | Participants in the disease group had history of stroke, confirmed by MRI and CT | Yes | |||
| RE = 94.06 ± 9.74 | RE = 43.35 ± 29.62 | ||||
| Yes | Participants in the disease group were diagnosed with cerebellar degeneration with high functioning | No | |||
| 3.8 Hz (SD = 1.6) | 20.9 Hz (SD = N/A) | ||||
| Yes | Participants in disease groups had mild to moderate Parkinson's disease, defined by Hoehn and Yahr ( | Yes | |||
| DurS = 98.89 ± 4.3 | DurS = 68.25 ± 36.65 | ||||
| Yes | Participants in disease groups had history of sport-related concussions, identified by the criteria from the American Academy of Neurology (Practice parameter 2000) and all athletes completed a Post-Concussive Symptom Checklist (Aubry et al., ( | No | |||
| N/A | Percent of errors from 3 concussed subjects were normal values (subject 3: RE = 30%; subject 5: LE = 54%; subject 6: RE = 33% and LE = 40%). | ||||
FPT, frequency pattern test; M:F, male:female; AEDs, antiepileptic drugs; TLE, temporal lobe epilepsy; RE, right ear; LE, left ear; DurS, duration with small perceptual distance; DurL, duration with large perceptual distance; RTLE, right temporal lobe epilepsy; LTLE, left temporal lobe epilepsy. Age was presented in years: mean ± SD or mean (range).
Figure 5Forest plot of meta-analysis for frequency pattern test (FPT), comparing between participants with documented brain disease and normal controls.
Figure 6Forest plot of frequency pattern test (FPT) for sensitivity analysis after excluding the studies by Troche et al. (31) and Elbeltagy et al. (24).
Figure 7Forest plot of meta-analysis for gaps-in-noise (GIN), comparing between participants with documented brain disease and normal controls.
Figure 8Forest plot of meta-analysis for gaps-in-noise (GIN) with subgroup analysis, categorized by the underlying conditions (stroke and temporal lobe epilepsy).